Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2026
Solid pseudopapillary neoplasm of the pancreas: A retrospective single-center cohort study of 1,058 consecutive patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Yi, Zhang Nuoyan, Song Yilin, Xiao Zhiwen, Liao Yina, Li Yiying, Shi Yang, Wang Xinyue, Ni Quanxing, Wang Lei, Yu Xianjun, Luo Guopei
Аннотация
BACKGROUND: Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare, low-grade malignant tumor, predominantly affecting young women. Although the overall prognosis of SPN is good, the understanding of its pathophysiological characteristics and the selection of treatment strategies remain insufficient.
METHODS: A retrospective analysis of 1058 consecutive patients with pathologically confirmed SPN was performed at a single institution. Clinicopathological characteristics, immunohistochemical profiles, targeted sequencing data, and overall survival were systematically evaluated.
RESULTS: The median age of the patients at diagnosis was 33 years, with females being the majority (78.1%). Most tumors were located in the body/tail (70.2%), larger than 3 cm (61.9%), while invasive features such as vascular invasion (1.6%), nerve invasion (7.0%), and lymph node metastasis (0.7%) were rare. Early-stage (stage I, II) patients were more common (99.1%). In recent years, the surgical procedures have significantly shifted towards minimally invasive and parenchyma-sparing surgery. The prognosis of SPN was excellent, with a 5-year survival of 97.9%. Molecular analysis revealed nearly universal CTNNB1 mutations (97%). High expression of progesterone receptor (PR, 97.2%) and low expression of estrogen receptor (ER, 7.7%) supported hormone dependence.
CONCLUSIONS: This large single-center cohort study confirms that SPN is a tumor with low malignant potential, and identifies the key clinicopathological and molecular factors associated with malignant features. Different hormone receptor profiles provide a theoretical basis for exploring hormone receptor-targeted therapy for advanced patients.
METHODS: A retrospective analysis of 1058 consecutive patients with pathologically confirmed SPN was performed at a single institution. Clinicopathological characteristics, immunohistochemical profiles, targeted sequencing data, and overall survival were systematically evaluated.
RESULTS: The median age of the patients at diagnosis was 33 years, with females being the majority (78.1%). Most tumors were located in the body/tail (70.2%), larger than 3 cm (61.9%), while invasive features such as vascular invasion (1.6%), nerve invasion (7.0%), and lymph node metastasis (0.7%) were rare. Early-stage (stage I, II) patients were more common (99.1%). In recent years, the surgical procedures have significantly shifted towards minimally invasive and parenchyma-sparing surgery. The prognosis of SPN was excellent, with a 5-year survival of 97.9%. Molecular analysis revealed nearly universal CTNNB1 mutations (97%). High expression of progesterone receptor (PR, 97.2%) and low expression of estrogen receptor (ER, 7.7%) supported hormone dependence.
CONCLUSIONS: This large single-center cohort study confirms that SPN is a tumor with low malignant potential, and identifies the key clinicopathological and molecular factors associated with malignant features. Different hormone receptor profiles provide a theoretical basis for exploring hormone receptor-targeted therapy for advanced patients.